FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2615672635> ?p ?o ?g. }

• W2615672635 endingPage "192" @default.
• W2615672635 startingPage "185" @default.
• W2615672635 abstract "Between 1988 and 1992, a randomized phase III clinical trial was conducted in China to compare three monthly injectable contraceptives: Mesigyna, Cyclofem and Injectable No. 1. This paper presents a detailed analysis of the menstrual diaries provided by 5098 (89%) of the subjects. In total, 902, 903 and 913 diaries were analyzed to compare bleeding patterns induced by Mesigyna, Cyclofem and Injectable No. 1. The first withdrawal bleeding usually occurs 14-20 days after the first injection for all three of these preparations. Thereafter, 50% of Mesigyna users had precisely 3 bleeding/spotting episodes every 90 days, 50% of Cyclofem users had 2-3 and 50% of Injectable No. 1 users had 3-4 episodes every 90 days. Relative to users of Mesigyna or Cyclofem, Injectable No. 1 users had 2-3 more bleeding/spotting days, and a shorter length of bleeding/spotting-free intervals in each period. 63.7%, 41.4% and 60.6% of subjects using Mesigyna, Cyclofem and Injectable No. 1, respectively, had bleeding patterns similar to their untreated patterns in the first 90-day period. The percentages increased to 82.2% 67.8% and 75.0% in the fourth 90-day period. A total of 1815 diaries for Mesigyna and 1802 for Cyclofem were analyzed for more in depth comparison of these two methods. The number of bleeding/spotting days over four periods showed little difference between the two group, but there were more spotting days and there was greater individual variability among Cyclofem users.(ABSTRACT TRUNCATED AT 250 WORDS)Between October 1988 and July 1990, a randomized multicentered phase III clinical trial was conducted in three provinces of China to compare three monthly injectable contraceptives (Mesigyna [50 mg norethisterone enanthate + 5 mg estradiol valerate], Cyclofem [25 mg medroxyprogesterone acetate + 5 mg estradiol cypionate], and Injectable No.1 [250 mg 17-hydroxyprogesterone caproate + 5 mg estradiol valerate]). A detailed analysis of the menstrual diaries of 5098 women aged 18-35 years compared the vaginal bleeding patterns associated with the injectables. Women in all three groups experienced more bleeding/spotting (B/S) days, more bleeding episodes, shorter bleeding-free intervals, and larger variability during the first 90 days than during the following three 90-day periods (p 0.001). 90% of Cyclofem users had 1-4 B/S episodes. 90% of Mesigyna users had 2-4.2 B/S episodes. Cyclofem users had more spotting days than did Mesigyna users in each 90-day period (5-8 vs. 5-6). Acceptable bleeding patterns (i.e., bleeding patterns similar to untreated patterns) predominated, on the most part, in all four periods (63.7-82.2% for Mesigyna users, 41.4-67.8% for Cyclofem users, and 60.6-75% for Injectable No.1 users). Acceptability increased with each 90-day period for all three injectables. Acceptability of bleeding patterns was much higher among Mesigyna users than Cyclofem users (p 0.001). Prolonged bleeding, followed by irregular bleeding and frequent bleeding, were the most common bleeding disturbances. Irregular bleeding decreased with time. 79.1% of Mesigyna and Cyclofem users who finished the study had an acceptable pattern. 70.7% of women who stopped for non-bleeding reasons had an acceptable pattern compared to 31.3% of those who stopped for bleeding reasons. These findings show that Mesigyna users experienced better cycle control and more acceptable bleeding patterns than did the users of the other two injectables." @default.
• W2615672635 created "2017-05-26" @default.
• W2615672635 creator A5009205090 @default.
• W2615672635 creator A5013277996 @default.
• W2615672635 creator A5018981154 @default.
• W2615672635 creator A5019963049 @default.
• W2615672635 creator A5025477536 @default.
• W2615672635 creator A5037823289 @default.
• W2615672635 creator A5040487354 @default.
• W2615672635 creator A5049432554 @default.
• W2615672635 creator A5053629813 @default.
• W2615672635 creator A5069290077 @default.
• W2615672635 date "1995-03-01" @default.
• W2615672635 modified "2023-10-16" @default.
• W2615672635 title "A multicentred phase III comparative clinical trial of Mesigyna, Cyclofem and Injectable No.1 given by intramuscular injection to Chinese women" @default.
• W2615672635 cites W1740052826 @default.
• W2615672635 cites W2003708256 @default.
• W2615672635 cites W2030656284 @default.
• W2615672635 cites W2052031497 @default.
• W2615672635 cites W2081376262 @default.
• W2615672635 doi "https://doi.org/10.1016/0010-7824(95)00014-2" @default.
• W2615672635 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7621686" @default.
• W2615672635 hasPublicationYear "1995" @default.
• W2615672635 type Work @default.
• W2615672635 sameAs 2615672635 @default.
• W2615672635 citedByCount "18" @default.
• W2615672635 countsByYear W26156726352012 @default.
• W2615672635 countsByYear W26156726352014 @default.
• W2615672635 crossrefType "journal-article" @default.
• W2615672635 hasAuthorship W2615672635A5009205090 @default.
• W2615672635 hasAuthorship W2615672635A5013277996 @default.
• W2615672635 hasAuthorship W2615672635A5018981154 @default.
• W2615672635 hasAuthorship W2615672635A5019963049 @default.
• W2615672635 hasAuthorship W2615672635A5025477536 @default.
• W2615672635 hasAuthorship W2615672635A5037823289 @default.
• W2615672635 hasAuthorship W2615672635A5040487354 @default.
• W2615672635 hasAuthorship W2615672635A5049432554 @default.
• W2615672635 hasAuthorship W2615672635A5053629813 @default.
• W2615672635 hasAuthorship W2615672635A5069290077 @default.
• W2615672635 hasConcept C120665830 @default.
• W2615672635 hasConcept C121332964 @default.
• W2615672635 hasConcept C141071460 @default.
• W2615672635 hasConcept C168563851 @default.
• W2615672635 hasConcept C2777902738 @default.
• W2615672635 hasConcept C2779076696 @default.
• W2615672635 hasConcept C2779506182 @default.
• W2615672635 hasConcept C2908647359 @default.
• W2615672635 hasConcept C2909635826 @default.
• W2615672635 hasConcept C29456083 @default.
• W2615672635 hasConcept C2986817661 @default.
• W2615672635 hasConcept C71924100 @default.
• W2615672635 hasConcept C99454951 @default.
• W2615672635 hasConceptScore W2615672635C120665830 @default.
• W2615672635 hasConceptScore W2615672635C121332964 @default.
• W2615672635 hasConceptScore W2615672635C141071460 @default.
• W2615672635 hasConceptScore W2615672635C168563851 @default.
• W2615672635 hasConceptScore W2615672635C2777902738 @default.
• W2615672635 hasConceptScore W2615672635C2779076696 @default.
• W2615672635 hasConceptScore W2615672635C2779506182 @default.
• W2615672635 hasConceptScore W2615672635C2908647359 @default.
• W2615672635 hasConceptScore W2615672635C2909635826 @default.
• W2615672635 hasConceptScore W2615672635C29456083 @default.
• W2615672635 hasConceptScore W2615672635C2986817661 @default.
• W2615672635 hasConceptScore W2615672635C71924100 @default.
• W2615672635 hasConceptScore W2615672635C99454951 @default.
• W2615672635 hasIssue "3" @default.
• W2615672635 hasLocation W26156726351 @default.
• W2615672635 hasLocation W26156726352 @default.
• W2615672635 hasOpenAccess W2615672635 @default.
• W2615672635 hasPrimaryLocation W26156726351 @default.
• W2615672635 hasRelatedWork W1586374228 @default.
• W2615672635 hasRelatedWork W2003938723 @default.
• W2615672635 hasRelatedWork W2047967234 @default.
• W2615672635 hasRelatedWork W2118496982 @default.
• W2615672635 hasRelatedWork W2364998975 @default.
• W2615672635 hasRelatedWork W2369162477 @default.
• W2615672635 hasRelatedWork W2439875401 @default.
• W2615672635 hasRelatedWork W4238867864 @default.
• W2615672635 hasRelatedWork W2525756941 @default.
• W2615672635 hasRelatedWork W2625280168 @default.
• W2615672635 hasVolume "51" @default.
• W2615672635 isParatext "false" @default.
• W2615672635 isRetracted "false" @default.
• W2615672635 magId "2615672635" @default.
• W2615672635 workType "article" @default.